利福昔明、益生菌与L-鸟氨酸L-天冬氨酸治疗显性肝性脑病疗效比较:一项随机IV期乳果糖对照临床试验
该试验为单中心、平行、多臂、随机、非盲、乳果糖对照的IV期临床试验,计划纳入252例18-80岁显性肝性脑病患者,每组63例,比较乳果糖单用及分别联合利福昔明、益生菌或L-鸟氨酸L-天冬氨酸四组方案。主要结局为第5天肝性脑病分级逆转,次要结局包括住院时间、恢复时间、药物不良反应监测及按死因分析的死亡。
要点
- 四组分别为乳果糖对照组、利福昔明联合乳果糖组、益生菌联合乳果糖组、L-鸟氨酸L-天冬氨酸联合乳果糖组,每组63例。
- 主要结局为第5天显性肝性脑病分级逆转,次要结局包括住院时间、恢复时间、药物不良反应及按死因分析的死亡。
- 研究为单中心、平行、多臂、随机、非盲、乳果糖对照IV期临床试验,计划纳入252例18-80岁患者。
核心结论
- 该随机对照试验方案旨在比较四组药物方案治疗显性肝性脑病的疗效,以填补当前认知空白。
研究设计与样本
- 单中心、平行、多臂、随机、非盲、乳果糖对照IV期临床试验,计划纳入252例18-80岁男性及女性患者,每组63例,从入组至治疗结束(第1至5天)进行观察。
主要发现
- 原文未报告结果,仅描述研究方案与结局指标。
关键数值与推荐
- 主要结局为评估第5天显性肝性脑病分级逆转。
- 次要结局为确定住院时间与恢复时间(天)、监测药物不良反应及按死因分析的死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pakistan has a high prevalence of HCV and HBV, causing cirrhosis, leading to hepatic encephalopathy in approximately 30-45% of cirrhotic patients. Overt hepatic encephalopathy (OHE) is a serious type of hepatic encephalopathy that refers to brain dysfunction resulting from acute or chronic liver disease. Patients present flapping tremors and mental alterations leading to a coma, which disrupts daily activities and patient health-related quality of life. OHE can be treated by lactulose, rifaximin, probiotics, and L-ornithine L-aspartate (LOLA). Lactulose (controlled drug for trial) is the main treatment for OHE, even though its effectiveness in clinical trials has remained varied. Rifaximin (interventional drug), probiotics (interventional drug), and LOLA (interventional drug) all showed a significant effect in reducing the grade of hepatic encephalopathy, lowering blood ammonia levels, and enhancing psychomotor function in OHE patients. Our trial aims to determine the most effective treatment combination, as despite the availability of multiple treatment options, the efficacy is still uncertain. Limited studies have compared individual treatments, but no research has been conducted to assess all four treatment groups together, i.e., Group A (lactulose) as the control group, Group B (rifaximin + lactulose), Group C (probiotics + lactulose), and Group D (LOLA + lactulose). METHODS: This trial is a single-center, parallel, multi-arm, randomized, unblinded, lactulose-controlled clinical trial. A total of 252 patients (both male and female aged 18-80 years), 63 in each treatment group, will be recruited in the study from the time of participation in the trial until the end of treatment (days 1-5). Primary outcome is to assess grade reversal of OHE on day 5 of trial participation. The secondary outcome is to determine the length of hospital stay and recovery time (days), monitoring of adverse drug reactions and death by cause in OHE patients. DISCUSSION: This randomized controlled trial protocol will compare the efficacy of four proposed groups of medications to fill the gap in current knowledge. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2300075925, registered on 19 September 2023; ClinicalTrials.gov NCT07037394, registered on 24 June 2025. Released to the public on 26 June 2025.
引用
- Shahbaz A, Jamil Q, Iqbal SM, et al. Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial. Trials. 2025. PMID: 41272855. doi:10.1186/s13063-025-09173-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。